Acmg Cnv Calculator

Estimate an educational ACMG and ClinGen style copy number variant point score using a practical evidence model for deletions and duplications. This tool helps summarize evidence strength, show a point breakdown, and visualize how individual criteria influence the final classification.

This calculator is an educational approximation of the ACMG and ClinGen point-based CNV framework. Clinical classification should always be finalized by a qualified laboratory professional using full case-level evidence and current guidance.

Expert Guide to the ACMG CNV Calculator

An ACMG CNV calculator is designed to help organize the evidence used when classifying copy number variants, especially deletions and duplications identified by chromosomal microarray, exome analysis, or genome sequencing. The core idea is straightforward: instead of making a subjective call based only on CNV size, a modern interpretation weighs multiple evidence lines, converts them into a point total, and maps that total to a classification such as pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or benign.

If you work in clinical genetics, molecular pathology, prenatal diagnosis, pediatrics, or genetic counseling, a structured calculator is valuable because it improves consistency. It creates an audit trail for why a CNV was scored the way it was, and it makes communication easier across multidisciplinary teams. The calculator above is built as an educational point-based model aligned with the logic of ACMG and ClinGen CNV interpretation standards.

What the ACMG CNV framework tries to solve

Before standardized scoring systems became widely used, CNV interpretation often leaned too heavily on rough heuristics such as overall CNV size, whether a result was inherited, or whether the lab had seen a similar event before. Those clues still matter, but they are not enough on their own. A small deletion involving a dosage sensitive gene may be highly pathogenic, while a much larger duplication in a gene-poor region may be benign or uncertain. The ACMG and ClinGen approach formalized a point-based workflow so that genomic content, overlap with established regions, inheritance, case evidence, and phenotype data all contribute to the final call.

High value principle: CNV interpretation is evidence-weighted, not size-only. The same 1 Mb CNV can classify very differently depending on gene content, known syndrome overlap, segregation, and population data.

How to use this calculator properly

1. Select the CNV type. Choose deletion for copy loss or duplication for copy gain.
2. Enter the CNV size in kilobases. This adds supportive weight in the educational model, but only in context with other evidence.
3. Record the number of affected coding genes. Gene content matters because a CNV that interrupts more clinically relevant genes often has a higher chance of significance.
4. Choose overlap with known pathogenic regions. Recurrent genomic syndromes and dosage sensitive loci can strongly shift the score upward.
5. Choose overlap with benign or common regions. Frequent population CNVs and known benign intervals pull the score downward.
6. Add inheritance evidence. A confirmed de novo event can increase suspicion, while inheritance from an apparently unaffected parent may lower it, especially in a high-penetrance disorder context.
7. Add phenotype and case report support. Published case consistency and phenotype specificity can transform an otherwise uncertain event into a likely pathogenic one.

ACMG style score thresholds used in CNV interpretation

The modern point framework maps a cumulative score to a final interpretation category. The threshold table below reflects the commonly cited cutoffs used in CNV scoring discussions.

Classification	Score range	Interpretive meaning
Pathogenic	0.99 or higher	Strong cumulative evidence that the CNV is disease-causing in the relevant clinical context.
Likely pathogenic	0.90 to 0.98	Evidence is compelling but may still fall short of the highest certainty threshold.
Variant of uncertain significance	-0.89 to 0.89	Evidence is mixed, incomplete, or insufficient to support a benign or pathogenic conclusion.
Likely benign	-0.90 to -0.98	Evidence leans toward non-pathogenicity, but may not meet full benign confidence.
Benign	-0.99 or lower	Strong evidence indicates the CNV is not clinically significant.

Why this matters clinically

CNVs are among the most important variant types in genomic medicine. They contribute to developmental delay, intellectual disability, autism spectrum disorder, multiple congenital anomalies, epilepsy, cardiovascular malformations, and a wide range of rare disease phenotypes. In prenatal settings, CNV interpretation can influence reproductive counseling, follow-up imaging, and perinatal management. In pediatric and adult diagnostics, a correctly classified CNV may end a diagnostic odyssey, refine surveillance recommendations, and allow targeted family counseling.

However, a CNV calculator should never be confused with a standalone diagnostic device. The real strength of the ACMG and ClinGen method is that it structures judgment rather than replacing it. For example, a duplication can be difficult to interpret even when large, because triplosensitivity evidence is less established for many loci than haploinsufficiency evidence. Likewise, inherited CNVs can still be pathogenic if penetrance is incomplete or expressivity is variable.

Evidence categories that most strongly influence a CNV score

1. Overlap with known pathogenic or benign regions

When a CNV substantially overlaps a recurrent genomic disorder region or a dosage sensitive interval curated by expert groups, the score can change quickly. This is one of the most efficient ways to move from uncertainty toward confidence. The opposite is also true. Strong overlap with common benign population CNVs or established benign regions can push a CNV toward likely benign or benign.

2. Inheritance and segregation

A de novo CNV in a patient with a fitting phenotype is often highly informative, especially when parental identity is confirmed and the phenotype is not easily explained by another finding. In contrast, a CNV inherited from an unaffected parent may reduce pathogenic confidence, but it should not automatically end the analysis. Reduced penetrance, sex-limited expression, mosaicism, or age-related presentation may complicate the picture.

3. Gene content and dosage sensitivity

The number of genes inside a CNV is a coarse metric, but it can still be helpful. A CNV that disrupts multiple dosage sensitive genes is generally more suspicious than one located in a gene-poor interval. Still, gene count is not the same as biological importance. One clinically relevant gene can matter more than fifty genes with no established dosage sensitivity.

4. Phenotype specificity and published case support

Published cases, patient databases, and phenotype matching are especially useful for rarer CNVs. If multiple independent cases describe a similar interval and a similar clinical picture, confidence increases. If the phenotype is highly specific for a recognized syndrome, this may provide substantial support even before long case series are available.

Diagnostic yield data that explain why CNV interpretation remains essential

CNV analysis is not just a niche laboratory exercise. It has measurable clinical impact. The comparison below summarizes commonly cited diagnostic or incremental detection figures from major clinical settings.

Clinical context	Test or comparison	Reported figure	Why it matters
Unexplained developmental delay, intellectual disability, autism spectrum disorder, or multiple congenital anomalies	Chromosomal microarray as a first-tier test	Approximately 15 to 20 percent diagnostic yield in many published series	This is why CNV interpretation remains a core skill in pediatric and neurodevelopmental genetics.
Same patient groups	Conventional karyotype	Roughly 3 percent yield for clinically relevant findings in many historical comparisons	Microarray detects submicroscopic CNVs missed by standard cytogenetics.
Prenatal diagnosis with a normal karyotype	Microarray added findings beyond karyotype	About 1.7 percent additional clinically significant CNVs in standard prenatal indications	Even when karyotype is normal, clinically important CNVs can still be present.
Prenatal diagnosis with fetal structural anomalies	Microarray added findings beyond karyotype	About 6.0 percent additional clinically significant CNVs	The added yield is especially important when ultrasound anomalies are present.

These figures highlight a practical truth: laboratories need a reliable way to interpret copy number changes because they are common, clinically significant, and frequently actionable. A calculator helps standardize that work, especially when several analysts or clinicians review the same case.

Best practices when interpreting an ACMG CNV score

• Always confirm genomic coordinates, assembly version, and CNV type before scoring.
• Review dosage sensitivity resources and curated syndrome regions before relying on size alone.
• Consider inheritance in context. A negative family history does not equal de novo status.
• Check whether the phenotype truly matches the affected genes or syndrome region.
• Use population databases, internal lab data, and published case reports together.
• Document why each score contribution was assigned so another reviewer can reproduce the logic.

Common pitfalls

One of the most common mistakes is overcalling large duplications as pathogenic simply because they are large. Another is undercalling smaller deletions that hit a well-established haploinsufficient gene. A third pitfall is treating inheritance from an unaffected parent as definitive evidence against pathogenicity in disorders with reduced penetrance. Finally, many labs underestimate the value of phenotype quality. A very precise phenotype can be more informative than a modest size increase.

Where to verify evidence with authoritative resources

For foundational background on copy number variation, review the National Human Genome Research Institute glossary at genome.gov. To explore clinically submitted variant assertions and supporting evidence, use ClinVar at NCBI. For broader public-facing genetics education and test interpretation basics, MedlinePlus Genetics offers a useful overview at medlineplus.gov.

How to interpret the chart in this calculator

After you run the calculator, the bar chart shows the relative impact of each evidence area. Positive bars indicate evidence pushing the CNV toward pathogenicity. Negative bars indicate evidence pushing the CNV toward benignity. This visual summary is useful in case conferences, sign-out preparation, and internal quality review because it quickly shows whether a result is driven by one dominant criterion or by multiple moderate contributors.

Final takeaways

An ACMG CNV calculator is best understood as a structured decision support tool. It helps convert genomic observations into a reproducible interpretation pathway. The most effective use case is not replacing expert review, but strengthening it. When used with validated databases, curated dosage sensitivity evidence, inheritance data, and phenotype correlation, a calculator can improve consistency, reduce interpretation drift, and make CNV classification more transparent.

Important: This page provides educational support for CNV evidence weighting. It is not a substitute for formal laboratory SOPs, current ACMG and ClinGen recommendations, or professional medical judgment.